Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 772 clinical trials
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients

ejection fraction
car t-cell therapy
multiple myeloma
lenalidomide
cellular therapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

oxygen saturation
ejection fraction
multiple myeloma
immunohistochemistry
refractory multiple myeloma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

multiple myeloma
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 1 location
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.

induction therapy
multiple myeloma
minimal residual disease
residual disease
  • 0 views
  • 19 Feb, 2024
  • 2 locations
A Study of CC-98633 BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to …

ixazomib
pomalidomide
carfilzomib
measurable disease
proteasome inhibitor
  • 0 views
  • 19 Feb, 2024
  • 9 locations
TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia. Both T-LGLL and CLPD-NK are indolent disease and share similar biology and clinical course, and treated under the same strategy.

lymphoproliferative disorder
prednisone
hepatosplenomegaly
leukemia
t-cell large granular lymphocytic leukemia
  • 0 views
  • 19 Feb, 2024
  • 9 locations
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

waldenstrom's macroglobulinemia
venetoclax
bone marrow biopsy
absolute neutrophil count
measurable disease
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

stem cell transplantation
multiple myeloma
high-dose chemotherapy
pain management
high dose chemotherapy
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

psychiatric disorder
oxygen saturation
mental illness
renal function test
ejection fraction
  • 0 views
  • 19 Feb, 2024
  • 1 location
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

oxygen saturation
stem cell transplantation
ejection fraction
remission
cell transplantation
  • 0 views
  • 19 Feb, 2024
  • 1 location